The Treatment Landscape for Indolent Systemic Mastocytosis
ISM Content Hub
In an interview conducted at the 64th Annual Scientific Meeting of the British Society for Haematology Congress, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, provides an overview of the therapeutic landscape for both indolent and advanced systemic mastocytosis. The approval of avapritinib for patients with indolent systemic mastocytosis in the United States was based on the results of the Phase 2 PIONEER trial. Additional tyrosine kinase inhibitors are under investigation in ongoing clinical trials.
